Privia Health Group, Inc. PRVA
We take great care to ensure that the data presented and summarized in this overview for Privia Health Group, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRVA
View all-
Black Rock Inc. New York, NY17.3MShares$366 Million0.01% of portfolio
-
Durable Capital Partners LP Bethesda, MD11.5MShares$244 Million2.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$239 Million0.0% of portfolio
-
Rubicon Founders LLC Nashville, TN5.77MShares$122 Million100.0% of portfolio
-
Riverbridge Partners LLC5.52MShares$117 Million2.07% of portfolio
-
State Street Corp Boston, MA4.11MShares$87.1 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA2.96MShares$62.7 Million0.04% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL2.63MShares$55.8 Million0.02% of portfolio
-
Bank Of America Corp Charlotte, NC2.56MShares$54.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.5MShares$52.9 Million0.0% of portfolio
Latest Institutional Activity in PRVA
Top Purchases
Top Sells
About PRVA
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.
Insider Transactions at PRVA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 21
2025
|
Thomas A Mc Carthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,396
+30.08%
|
-
|
May 21
2025
|
Patricia Anne Maryland Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,396
+16.56%
|
-
|
May 21
2025
|
Pamela O Kimmet Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,396
+24.62%
|
-
|
May 21
2025
|
Nancy G Cocozza Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,396
+19.64%
|
-
|
May 21
2025
|
David S Wichmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,396
+24.62%
|
-
|
May 21
2025
|
David P King Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,396
+16.56%
|
-
|
May 21
2025
|
Matthew Shawn Morris Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,396
+10.96%
|
-
|
May 21
2025
|
Jaewon Ryu Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,396
+17.85%
|
-
|
May 13
2025
|
Parth Mehrotra Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,909
-3.76%
|
$381,816
$24.52 P/Share
|
May 12
2025
|
David Mountcastle EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,322
-1.89%
|
$79,728
$24.99 P/Share
|
May 12
2025
|
Parth Mehrotra Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,773
-3.15%
|
$330,552
$24.99 P/Share
|
May 01
2025
|
Parth Mehrotra Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,365
-3.82%
|
$399,395
$23.08 P/Share
|
Apr 30
2025
|
Matthew Shawn Morris Director |
SELL
Open market or private sale
|
Direct |
10,309
-14.71%
|
$237,107
$23.33 P/Share
|
Apr 30
2025
|
David Mountcastle EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,445
-1.92%
|
$79,235
$23.33 P/Share
|
Apr 30
2025
|
Parth Mehrotra Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,100
-3.22%
|
$347,300
$23.33 P/Share
|
Apr 02
2025
|
David Mountcastle EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,630
-3.04%
|
$123,860
$22.38 P/Share
|
Mar 12
2025
|
Parth Mehrotra Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,514
-2.19%
|
$252,336
$24.03 P/Share
|
Mar 11
2025
|
Edward C Fargis EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
2,438
-2.55%
|
$56,074
$23.88 P/Share
|
Mar 11
2025
|
David Mountcastle EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,872
-1.53%
|
$66,056
$23.88 P/Share
|
Mar 11
2025
|
Parth Mehrotra Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,294
-1.9%
|
$213,762
$23.88 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 259K shares |
---|---|
Exercise of conversion of derivative security | 252K shares |
Bona fide gift | 53.5K shares |
Open market or private sale | 360K shares |
---|---|
Bona fide gift | 53.5K shares |